Are you Dr. Bradner?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 128 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
44 Binney St
Dana-Farber Cancer Institute
Boston, MA 02115Phone+1 617-632-6629Fax+1 617-632-5168
Summary
- Dr. James Bradner, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Dana-Farber Cancer Institute, Brigham and Women's Faulkner Hospital, and South Shore Hospital.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2002 - 2005- Brigham and Women's HospitalResidency, Internal Medicine, 1999 - 2002
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1999
Certifications & Licensure
MA State Medical License 2002 - 2025
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2011
Publications & Presentations
PubMed
- 2059 citationsSelective Inhibition of Tumor Oncogenes by Disruption of Super-EnhancersJakob Lovén, Heather A. Hoke, Charles Y. Lin, Ashley Lau, David A. Orlando
Cell. 2013-04-11 - 114 citationsLigand-Promoted Meta-C–H Arylation of Anilines, Phenols, and HeterocyclesPeng Wang, Marcus E. Farmer, Xing Huo, Pankaj Jain, Peng-Xiang Shen
Journal of the American Chemical Society. 2016-07-19 - 1206 citationsHDAC2 negatively regulates memory formation and synaptic plasticityJi-Song Guan, Stephen J. Haggarty, Emanuela Giacometti, Jan Hermen Dannenberg, Nadine F. Joseph
Nature. 2009-05-07
Press Mentions
Genetic Study Provides First-Ever Insight into Biological Origin of SchizophreniaJune 25th, 2020- Real-Time Transferrin-Based PET Detects MYC-Positive Prostate CancerJune 7th, 2020
SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in CancerJune 6th, 2019- Join now to see all
Grant Support
- Selective Inhibition Of HDAC6 In Cancer TherapyNational Cancer Institute2008–2011
